|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine
|
|
gptkbp:ATCCode
|
N05CD07
|
|
gptkbp:availableOn
|
gptkb:tablet
capsule
|
|
gptkbp:brand
|
gptkb:Restoril
|
|
gptkbp:CASNumber
|
846-50-4
|
|
gptkbp:category
|
benzodiazepine
sedative
muscle relaxant
hypnotic
|
|
gptkbp:chemicalFormula
|
C16H13ClN2O2
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
pregnancy
severe respiratory insufficiency
sleep apnea syndrome
|
|
gptkbp:developedBy
|
gptkb:Milan_Hašek
|
|
gptkbp:discoveredBy
|
gptkb:Milan_Hašek
|
|
gptkbp:eliminationHalfLife
|
8–20 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Temazepam
|
|
gptkbp:interactsWith
|
gptkb:beer
opioids
other CNS depressants
|
|
gptkbp:legalStatus
|
gptkb:Schedule_IV_controlled_substance_(US)
prescription only
|
|
gptkbp:marketedAs
|
1970s
|
|
gptkbp:mechanismOfAction
|
positive allosteric modulator of GABA-A receptor
|
|
gptkbp:medicalUseApproved
|
1969
|
|
gptkbp:meltingPoint
|
163–164 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseSymptoms
|
coma
respiratory depression
death (rare)
excessive sedation
|
|
gptkbp:patent
|
1965
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:PubChem_CID
|
5391
DB00231
|
|
gptkbp:riskOfDependence
|
yes
|
|
gptkbp:riskOfWithdrawal
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:center
confusion
dizziness
fatigue
headache
drowsiness
impaired coordination
|
|
gptkbp:UNII
|
CHB49036V1
|
|
gptkbp:usedFor
|
sleep disorders
insomnia
|
|
gptkbp:bfsParent
|
gptkb:Benzodiazepines
|
|
gptkbp:bfsLayer
|
6
|